Aberdeen Group
ARQT icon

Aberdeen Group’s Arcutis Biotherapeutics ARQT Stock Holding History

Aberdeen Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.8M Buy
1,098,411
+453,345
+70% +$10.6M 0.04% 342
2026
Q1 		$15.2M Buy
645,066
+58,669
+10% +$1.5M 0.02% 492
2025
Q4 		$17M Sell
586,397
-88,637
-13% -$2.27M 0.03% 481
2025
Q3 		$12.7M Hold
675,034
– – 0.02% 560
2025
Q2 		$9.46M Buy
675,034
+87,494
+15% +$1.23M 0.02% 607
2025
Q1 		$9.19M Buy
587,540
+105,466
+22% +$1.49M 0.02% 580
2024
Q4 		$6.72M Hold
482,074
– – 0.01% 591
2024
Q3 		$4.48M Buy
482,074
+333,200
+224% +$3.29M 0.01% 664
2024
Q2 		$1.38M Hold
148,874
– – ﹤0.01% 792
2024
Q1 		$1.48M Hold
148,874
– – ﹤0.01% 801
2023
Q4 		$481K Buy
+148,874
New +$405K ﹤0.01% 886

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Aberdeen Group's ARQT Position: Q2 2026 in Review

Aberdeen Group increased its Arcutis Biotherapeutics (ARQT) stake by 70% in Q2 2026, buying an estimated $10.6M and bringing the position to 1,098,411 shares worth $28.8M. The position accounts for 0.04% of the portfolio, ranked #342.

Aberdeen Group first reported a position in ARQT in Q4 2023 and has held it in 11 quarters since. 273 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • Aberdeen Group held 1,098,411 shares of Arcutis Biotherapeutics worth $28.8M as of Q2 2026.
  • Aberdeen Group bought 453,345 Arcutis Biotherapeutics shares in Q2 2026, an estimated $10.6M.
  • Arcutis Biotherapeutics made up 0.04% of Aberdeen Group's portfolio in Q2 2026, its #342 holding.
  • Aberdeen Group first reported a position in Arcutis Biotherapeutics in Q4 2023 and has held it in 11 quarters since.
  • 273 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on Aberdeen Group's 13F filing for Q2 2026, filed 31 Jul 2026.